WAS
ABBV icon

WESPAC Advisors SoCal’s AbbVie ABBV Stock Holding History

WESPAC Advisors SoCal’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-34,502
Closed -$5.58M – 88
2022
Q4 		$5.58M Buy
34,502
+479
+1% +$73.4K 2.07% 19
2022
Q3 		$4.98M Sell
34,023
-478
-1% -$68.6K 2.08% 20
2022
Q2 		$5.28M Sell
34,501
-616
-2% -$94.1K 2.02% 23
2022
Q1 		$5.69M Sell
35,117
-25,152
-42% -$3.65M 1.76% 25
2021
Q4 		$8.26M Sell
60,269
-3,357
-5% -$397K 2.52% 16
2021
Q3 		$6.97M Sell
63,626
-22,941
-27% -$2.62M 2.28% 21
2021
Q2 		$9.75M Buy
86,567
+2,370
+3% +$267K 3.23% 7
2021
Q1 		$9.11M Sell
84,197
-11,973
-12% -$1.28M 3.57% 9
2020
Q4 		$10.3M Buy
96,170
+28,010
+41% +$2.69M 4.09% 6
2020
Q3 		$5.98M Buy
68,160
+55,740
+449% +$5.25M 2.85% 17
2020
Q2 		$1.2M Sell
12,420
-1,225
-9% -$108K 0.56% 34
2020
Q1 		$1.14M Sell
13,645
-2,000
-13% -$170K 0.63% 28
2019
Q4 		$1.39M Sell
15,645
-720
-4% -$59.8K 0.66% 30
2019
Q3 		$1.24M Buy
16,365
+225
+1% +$15.4K 0.61% 34
2019
Q2 		$1.17M Buy
16,140
+5,844
+57% +$459K 0.63% 35
2019
Q1 		$829K Sell
10,296
-825
-7% -$67.5K 0.46% 39
2018
Q4 		$1.02M Sell
11,121
-1,128
-9% -$99.2K 0.65% 30
2018
Q3 		$1.16M Buy
12,249
+775
+7% +$73.5K 0.58% 37
2018
Q2 		$1.06M Sell
11,474
-291
-2% -$28.4K 0.61% 35
2018
Q1 		$1.11M Buy
11,765
+315
+3% +$34.6K 0.64% 35
2017
Q4 		$2.15M Sell
11,450
-250
-2% -$23.6K 1.22% 28
2017
Q3 		$1.04M Sell
11,700
-425
-4% -$32.4K 0.62% 33
2017
Q2 		$879K Sell
12,125
-75
-0.6% -$5.04K 0.56% 33
2017
Q1 		$795K Buy
12,200
+1,700
+16% +$107K 0.49% 35
2016
Q4 		$658K Sell
10,500
-250
-2% -$15.3K 0.43% 35
2016
Q3 		$678K Buy
10,750
+650
+6% +$42.1K 0.46% 42
2016
Q2 		$625K Buy
+10,100
New +$615K 0.41% 41

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

WESPAC Advisors SoCal's ABBV Position: Q1 2023 in Review

WESPAC Advisors SoCal sold out of AbbVie (ABBV) in Q1 2023, closing a stake of 34,502 shares — an estimated $5.58M sold.

WESPAC Advisors SoCal first reported a position in ABBV in Q2 2016 and held it in 27 quarters. The position peaked at $10.3M in Q4 2020. 3,138 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

  • WESPAC Advisors SoCal reported no remaining AbbVie position as of Q1 2023 after selling out during the quarter.
  • WESPAC Advisors SoCal sold 34,502 AbbVie shares in Q1 2023, an estimated $5.58M.
  • WESPAC Advisors SoCal first reported a position in AbbVie in Q2 2016 and held it in 27 quarters.
  • WESPAC Advisors SoCal's AbbVie position peaked at $10.3M in Q4 2020.
  • 3,138 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on WESPAC Advisors SoCal's 13F filing for Q1 2023, filed 15 May 2023.